Bronchiectasis - Pipeline Review, H1 2020
Bronchiectasis - Pipeline Review, H1 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bronchiectasis - Pipeline Review, H1 2020, provides an overview of the Bronchiectasis (Respiratory) pipeline landscape.
Bronchiectasis is a chronic condition where the walls of the bronchial tubes are permanently damaged. These damage allow bacteria and mucus to build up in lungs. Bronchiectasis is divided into two categories cystic fibrosis (CF) bronchiectasis and non-CF bronchiectasis. Symptoms include chronic coughing, shortness of breath, chest pain, fatigue, weight loss and fever. Causes of bronchiectasis include inhaling foreign object, cystic fibrosis, GERD and weakness in immune system. Treatment includes antibiotics to fight infection, bronchodilators, expectorants and mucolytic agents.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bronchiectasis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Bronchiectasis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Bronchiectasis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Bronchiectasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 2, 6 and 2 respectively.
Bronchiectasis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bronchiectasis - Pipeline Review, H1 2020, provides an overview of the Bronchiectasis (Respiratory) pipeline landscape.
Bronchiectasis is a chronic condition where the walls of the bronchial tubes are permanently damaged. These damage allow bacteria and mucus to build up in lungs. Bronchiectasis is divided into two categories cystic fibrosis (CF) bronchiectasis and non-CF bronchiectasis. Symptoms include chronic coughing, shortness of breath, chest pain, fatigue, weight loss and fever. Causes of bronchiectasis include inhaling foreign object, cystic fibrosis, GERD and weakness in immune system. Treatment includes antibiotics to fight infection, bronchodilators, expectorants and mucolytic agents.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bronchiectasis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Bronchiectasis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Bronchiectasis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Bronchiectasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 2, 6 and 2 respectively.
Bronchiectasis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Bronchiectasis (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Bronchiectasis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bronchiectasis (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bronchiectasis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bronchiectasis (Respiratory)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bronchiectasis (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bronchiectasis (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Bronchiectasis - Overview
Bronchiectasis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Bronchiectasis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bronchiectasis - Companies Involved in Therapeutics Development
Alitair Pharmaceuticals Inc
Chiesi Farmaceutici SpA
Helperby Therapeutics Group Ltd
Insmed Inc
Kamada Ltd
Novabiotics Ltd
OrPro Therapeutics Inc
Parion Sciences Inc
Polyphor AG
Recipharm AB
Santhera Pharmaceuticals Holding AG
Savara Inc
Therapeutic Systems Research Laboratories Inc
Zambon Co SpA
Bronchiectasis - Drug Profiles
alpha-1 proteinase inhibitor (human) second generation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
amikacin sulfate PR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARD-3150 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brensocatib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CHF-6333 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
doxofylline - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
erdosteine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HY-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
murepavadin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCFBE-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NM-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ORP-100S - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
POL-6014 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Bronchiectasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tobramycin + triclosan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bronchiectasis - Dormant Projects
Bronchiectasis - Discontinued Products
Bronchiectasis - Product Development Milestones
Featured News & Press Releases
Feb 03, 2020: Insmed announces positive top-line results from phase 2 WILLOW study of INS1007 in patients with Non-Cystic Fibrosis Bronchiectasis
Jun 07, 2019: Polyphor presents new in-vivo efficacy and tolerability data for a potential inhaled administration of its lead antibiotic murepavadin at the European Cystic Fibrosis Conference
Oct 12, 2017: Polyphor launches the development of an inhaled formulation of its antibiotic Murepavadin and joins a European consortium of leading hospitals and research institutions
May 03, 2017: Insmed Provides Update On Phase 2 Study Of INS1007
Apr 28, 2014: Erdosteine Received Orphan Drug Status by the FDA
Jan 07, 2014: Alitair Receives Orphan Drug Designation for Erdosteine in Bronchiectasis
Jun 24, 2013: Kamada Receives Two Key Patents Covering Its New Alpha-1 Antitrypsin Product
Jun 09, 2009: Kamada Reports Positive Proof-of-Concept Data for Inhaled Alpha-1 Antitrypsin in Bronchiectasis
Dec 16, 2008: Kamada Completes Enrollment in its Phase II Bronchiectasis Trial with Inhaled AAT
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Bronchiectasis - Overview
Bronchiectasis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Bronchiectasis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bronchiectasis - Companies Involved in Therapeutics Development
Alitair Pharmaceuticals Inc
Chiesi Farmaceutici SpA
Helperby Therapeutics Group Ltd
Insmed Inc
Kamada Ltd
Novabiotics Ltd
OrPro Therapeutics Inc
Parion Sciences Inc
Polyphor AG
Recipharm AB
Santhera Pharmaceuticals Holding AG
Savara Inc
Therapeutic Systems Research Laboratories Inc
Zambon Co SpA
Bronchiectasis - Drug Profiles
alpha-1 proteinase inhibitor (human) second generation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
amikacin sulfate PR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARD-3150 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brensocatib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CHF-6333 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
doxofylline - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
erdosteine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HY-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
murepavadin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCFBE-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NM-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ORP-100S - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
POL-6014 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Bronchiectasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tobramycin + triclosan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bronchiectasis - Dormant Projects
Bronchiectasis - Discontinued Products
Bronchiectasis - Product Development Milestones
Featured News & Press Releases
Feb 03, 2020: Insmed announces positive top-line results from phase 2 WILLOW study of INS1007 in patients with Non-Cystic Fibrosis Bronchiectasis
Jun 07, 2019: Polyphor presents new in-vivo efficacy and tolerability data for a potential inhaled administration of its lead antibiotic murepavadin at the European Cystic Fibrosis Conference
Oct 12, 2017: Polyphor launches the development of an inhaled formulation of its antibiotic Murepavadin and joins a European consortium of leading hospitals and research institutions
May 03, 2017: Insmed Provides Update On Phase 2 Study Of INS1007
Apr 28, 2014: Erdosteine Received Orphan Drug Status by the FDA
Jan 07, 2014: Alitair Receives Orphan Drug Designation for Erdosteine in Bronchiectasis
Jun 24, 2013: Kamada Receives Two Key Patents Covering Its New Alpha-1 Antitrypsin Product
Jun 09, 2009: Kamada Reports Positive Proof-of-Concept Data for Inhaled Alpha-1 Antitrypsin in Bronchiectasis
Dec 16, 2008: Kamada Completes Enrollment in its Phase II Bronchiectasis Trial with Inhaled AAT
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Bronchiectasis, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Bronchiectasis - Pipeline by Alitair Pharmaceuticals Inc, H1 2020
Bronchiectasis - Pipeline by Chiesi Farmaceutici SpA, H1 2020
Bronchiectasis - Pipeline by Helperby Therapeutics Group Ltd, H1 2020
Bronchiectasis - Pipeline by Insmed Inc, H1 2020
Bronchiectasis - Pipeline by Kamada Ltd, H1 2020
Bronchiectasis - Pipeline by Novabiotics Ltd, H1 2020
Bronchiectasis - Pipeline by OrPro Therapeutics Inc, H1 2020
Bronchiectasis - Pipeline by Parion Sciences Inc, H1 2020
Bronchiectasis - Pipeline by Polyphor AG, H1 2020
Bronchiectasis - Pipeline by Recipharm AB, H1 2020
Bronchiectasis - Pipeline by Santhera Pharmaceuticals Holding AG, H1 2020
Bronchiectasis - Pipeline by Savara Inc, H1 2020
Bronchiectasis - Pipeline by Therapeutic Systems Research Laboratories Inc, H1 2020
Bronchiectasis - Pipeline by Zambon Co SpA, H1 2020
Bronchiectasis - Dormant Projects, H1 2020
Bronchiectasis - Dormant Projects, H1 2020 (Contd..1), H1 2020
Bronchiectasis - Discontinued Products, H1 2020
Number of Products under Development for Bronchiectasis, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Bronchiectasis - Pipeline by Alitair Pharmaceuticals Inc, H1 2020
Bronchiectasis - Pipeline by Chiesi Farmaceutici SpA, H1 2020
Bronchiectasis - Pipeline by Helperby Therapeutics Group Ltd, H1 2020
Bronchiectasis - Pipeline by Insmed Inc, H1 2020
Bronchiectasis - Pipeline by Kamada Ltd, H1 2020
Bronchiectasis - Pipeline by Novabiotics Ltd, H1 2020
Bronchiectasis - Pipeline by OrPro Therapeutics Inc, H1 2020
Bronchiectasis - Pipeline by Parion Sciences Inc, H1 2020
Bronchiectasis - Pipeline by Polyphor AG, H1 2020
Bronchiectasis - Pipeline by Recipharm AB, H1 2020
Bronchiectasis - Pipeline by Santhera Pharmaceuticals Holding AG, H1 2020
Bronchiectasis - Pipeline by Savara Inc, H1 2020
Bronchiectasis - Pipeline by Therapeutic Systems Research Laboratories Inc, H1 2020
Bronchiectasis - Pipeline by Zambon Co SpA, H1 2020
Bronchiectasis - Dormant Projects, H1 2020
Bronchiectasis - Dormant Projects, H1 2020 (Contd..1), H1 2020
Bronchiectasis - Discontinued Products, H1 2020
LIST OF FIGURES
Number of Products under Development for Bronchiectasis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Alitair Pharmaceuticals Inc
Chiesi Farmaceutici SpA
Helperby Therapeutics Group Ltd
Insmed Inc
Kamada Ltd
Novabiotics Ltd
OrPro Therapeutics Inc
Parion Sciences Inc
Polyphor AG
Recipharm AB
Santhera Pharmaceuticals Holding AG
Savara Inc
Therapeutic Systems Research Laboratories Inc
Zambon Co SpA
Number of Products under Development for Bronchiectasis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Alitair Pharmaceuticals Inc
Chiesi Farmaceutici SpA
Helperby Therapeutics Group Ltd
Insmed Inc
Kamada Ltd
Novabiotics Ltd
OrPro Therapeutics Inc
Parion Sciences Inc
Polyphor AG
Recipharm AB
Santhera Pharmaceuticals Holding AG
Savara Inc
Therapeutic Systems Research Laboratories Inc
Zambon Co SpA
